Step 1 - lupus / diabetes / alzheimers syrum - Take 5ml blood
Contact Josh@mexicoassistedliving.com for more information about this amazing stem cell medicine that is helping to treat people with lupus, anti-immune disorders, alzheimers, diabetes type...

By: Joshua Ketner

Visit link:
Step 1 - lupus / diabetes / alzheimers syrum - Take 5ml blood - Video

3 hours ago New genetic barcoding technology allows scientists to identify differences in origin between individual blood cells. Credit: Camargo Lab

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Children's Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells. The researchers hypothesize that blood comes from stable populations of different long-lived progenitor cells that are responsible for giving rise to specific blood cell types, while blood stem cells likely act as essential reserves.

The work, supported by a National Institutes of Health Director's New Innovator Award and published in Nature, suggests that progenitor cells could potentially be just as valuable as blood stem cells for blood regeneration therapies.

This new research challenges what textbooks have long read: That blood stem cells maintain the day-to-day renewal of blood, a conclusion drawn from their importance in re-establishing blood cell populations after bone marrow transplantsa fact that still remains true. But because of a lack of tools to study how blood forms in a normal context, nobody had been able to track the origin of blood cells without doing a transplant.

Boston Children's Hospital scientist Fernando Camargo, PhD, and his postdoctoral fellow Jianlong Sun, PhD, addressed this problem with a tool that generates a unique barcode in the DNA of all blood stem cells and their progenitor cells in a mouse. When a tagged cell divides, all of its descendant cells possess the same barcode. This biological inventory system makes it possible to determine the number of stem cells/progenitors being used to make blood and how long they live, as well as answer fundamental questions about where individual blood cells come from.

"There's never been such a robust experimental method that could allow people to look at lineage relationships between mature cell types in the body without doing transplantation," Sun said. "One of the major directions we can now go is to revisit the entire blood cell hierarchy and see how the current knowledge holds true when we use this internal labeling system."

"People have tried using viruses to tag blood cells in the past, but the cells needed to be taken out of the body, infected, and re-transplanted, which raised a number of issues," said Camargo, who is a member of Children's Stem Cell Program and an associate professor in Harvard University's Department of Stem Cell and Regenerative Biology. "I wanted to figure out a way to label blood cells inside of the body, and the best idea I had was to use mobile genetic elements called transposons."

A transposon is a piece of genetic code that can jump to a random point in DNA when exposed to an enzyme called transposase. Camargo's approach works using transgenic mice that possess a single fish-derived transposon in all of their blood cells. When one of these mice is exposed to transposase, each of its blood cells' transposons changes location. The location in the DNA where a transposon moves acts as an individual cell's barcode, so that if the mouse's blood is taken a few months later, any cells with the same transposon location can be linked back to its parent cell.

The transposon barcode system took Camargo and Sun seven years to develop, and was one of Camargo's first projects when he opened his own lab at the Whitehead Institute for Biomedical Research directly out of grad school. Sun joined the project after three years of setbacks, and accomplished an experimental tour de force to reach the conclusions in the Nature paper, which includes data on how many stem cells or progenitor cells contribute to the formation of immune cells in mouse blood.

With the original question of how blood arises in a non-transplant context answered, the researchers are now planning to explore many more applications for their barcode tool.

The rest is here:
Barcoding tool for stem cells: New technology that tracks the origin of blood cells challenges scientific dogma

Stem cell therapy of a dog in the Netherlands.
One a half years later he is juming and playing after first almost not being able not walk anymore. info@fat-stem.com.

By: Fat Stem NV

Go here to read the rest:
Stem cell therapy of a dog in the Netherlands. - Video

Published: Sat, October 4, 2014 @ 12:09 a.m.

By EMMALEE C. TORISK

etorisk@vindy.com

STRUTHERS

Missy Ginnetti began to tear up as she re-read a typed letter from her bone-marrow donor.

Sitting at her kitchen table, with her husband, Mahoning County Engineer Pat Ginnetti, across from her, Missy explained that she doesnt know anything specific a name, an occupation, a city of residence about her donor. In fact, any bits of potentially revealing information, no matter how seemingly minute or insignificant, were blacked out of the letter.

What wasnt, however, was her donors closing: Sincerely, The other part of your marrow.

I wrote back, Dear All of my marrow, Missy said, laughing.

Its true. Within 30 days of her allogeneic stem-cell transplant in late March, Missys body had accepted 100 percent of the donor cells something that often doesnt happen for up to a year afterward.

Now, more than four years after Missys initial diagnosis of stage 3 Hodgkin lymphoma, life for the Ginnettis is beginning to move closer to normal once again. The next big thing, she said, is undergoing tests and scans within the next couple of weeks that will reveal whether cancer cells [are] showing up anywhere.

Excerpt from:
Unknown donor helps Struthers woman through cancer battle

Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Instagram: http://instagram.com/drbilljo...

By: dallasdrj

Read this article:
Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling - Video

HOUSTON -

Stem cells, the body's so called "master cells," are used to treat heart disease and cancer and to grow tissue. But plants also have stem cells and they're some of the hottest ingredients in anti-aging products.

Andrea Vizcaino, 49, is trying out a new phyto-facial that comes in the form of a freeze dried serum in a vial. One of the main ingredients is stem cells from the argon tree in Morocco. She described the procedure.

"It feels warm, especially around my chin and it feels good," said Vizcaino. "Very hydrating; the skin feels moist."

Apple, echinacea and grape stem cells are already used in many skin care products, but some scientists think the argon tree cells will penetrate even deeper.

"The plant stem cells stimulate our stem cells to regenerate the skin," said skin care specialist Candy Bonura.

Allenby agrees the new products can be hydrating, but said the jury is still out about the real effectiveness of plant stem cells.

"Stem cells are kind of the buzz word right now, but we have to remember that stem cells are different in plants and different in people," Allenby said.

Bonura acknowledged these new products won't take years off your face, but many clients do see a difference.

"I see a brightening, I see a hydration, I also see the skin is more supple looking and more youthful with a glow to it," Bonura said.

Here is the original post:
Plant stem cells may help skin look younger, healthier

Stem Cell Indonesia | Stem Cell Therapy | 0818 09055022
Stem Cell Indonesia Stem Cell Therapy Info: http://www.fullofblessings.jeunesseglobal.com 2A9F978E / +62818 09055022.

By: Stem Cell Indonesia

The rest is here:
Stem Cell Indonesia | Stem Cell Therapy | 0818 09055022 - Video

Boston, Massachusetts (PRWEB) September 25, 2014

The ASCTCs (website) Director James L. Sherleys first BioPharm America (conference website) experience got off to a remarkable beginning on Day 1 of the conference. After an impromptu decision to participate in the events Perfect Pitch competition, which involved about 40 company contestants, ASCTC tied for second place. As one of a few companies in the stem cell and regenerative medicine space at the conference, this success led to some attendees referring to Sherley as that stem cell guy. Sherley smiled, I take it as a fun compliment. I do think it was the unique presence of ASCTC as one of a few stem cell companies present in a sea of drug development companies that contributed to our success.

However, the ASCTCs pitch to a panel of Pharma investors was in fact more about drugs than stem cells. Sherley pitched the companys partnership venture with AlphaSTAR Corporation (ASC; website) located in Long Beach, California. ASC develops computer simulation analyses to predict the integrity failure of complex composite materials used to build aircraft, racing cars, and other high stress vehicles like the space shuttle. The two companies have integrated their respective expertise to produce a first-of-its-kind computer simulation-based technology for identifying, at the beginning of the drug development pipeline, drug candidates that are toxic to tissue stem cells. Such toxicity causes drugs to fail in expensive preclinical studies and clinical trials, and even after marketing.

At the conference, Sherley commented, I think we are starting to get their [drug companies] attention now. In his pitch of the new AlphaStem tissue stem cell toxicity technology, he emphasized that the ASCTC projects that this technology could save the U.S. Pharma industry about $4 billion of the estimated $40 billion that it spends on failed drug candidates each year. Besides reducing cost and accelerating the development of needed new drugs, the AlphaStem technology would reduce that exposure of patients to particularly harmful drug candidates.

The ASCTC was not the only company at the conference active within the regenerative medicine space. On the first evening of the conference, ASCTC was one of several guest companies and academic institutions in the regenerative medicine space that were invited to a VIP dinner co-hosted by BioPharm Americas producer, EBD Group, and the Alliance for Regenerative Medicine. The guest party dined at the Top of the Hub Restaurant on the top floor of Bostons Prudential Tower.

BioPharm America conferences are designed to arrange many one-to-one meetings among participants of diverse expertise in the international pharmaceutical industry. Over the three-day conference, ASCTC Director Sherley met with Pharma executives, contract research organization directors, Pharma business development consultants, and Pharma investment group partners towards establishing new strategic relationships for the company.

On the final morning of the conference, the ASCTC was one of eleven companies selected to present in the Next Generation Company session. Director Sherley focused his presentation on how the ASCTCs unique expertise in tissue stem cell asymmetric self-renewal gives the company its exclusive position in commercialization of technologies for counting, manufacturing, and monitoring human tissue stem cells. Asymmetric self-renewal is the defining property of tissue stem cells that allows them to maintain the genomic blueprint of human tissues while continuously producing the building block cells of body tissues at the same time. Sherley expressed that asymmetrically self-renewing stem cells in organs and tissues of children and adults will eventually be understood as the fulcrum at the center, between the mature industry of pharmaceutical therapeutics and the emerging industry of cell-based therapeutics. Thats the ASCTC vision.

************************************************************************************************************* The Adult Stem Cell Technology Center, LLC is a Massachusetts life sciences company established in September 2013 (ASCTC; join mailing list). ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the three main technical problems production, quantification, and monitoring that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

More here:
The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America ...

Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD)
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the article here:
Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - Video

PUBLIC RELEASE DATE:

24-Sep-2014

Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society @ACSpressroom

The liver provides critical functions, such as ridding the body of toxins. Its failure can be deadly, and there are few options for fixing it. But scientists now report in the journal ACS Applied Materials & Interfaces a way to potentially inject stem cells from tonsils, a body part we don't need, to repair damaged livers all without surgery.

Byeongmoon Jeong and colleagues point out that currently, the only established method for treating liver failure or severe cases of liver disease is complete or partial transplantation. But the need is much greater than the number of available organs. Plus, surgery has inherent risks and a hefty price tag. A promising alternative in development is transplanting liver cells. One such approach involves using adult stem cells to make liver cells. Stem cells from bone marrow could be used, but they have limitations. Recently, scientists identified another source of adult stem cells that could be used for this purpose tonsils. Every year, thousands of surgeries are performed to remove tonsils, and the tissue is discarded. Now it could have a new purpose, but scientists needed a way to grow them on a 3-D scaffold that mimics real liver tissue. Jeong's team set out to do just that.

The researchers encapsulated tonsil-derived stem cells in a heat-sensitive liquid that turns into a gel at body temperature. They added substances called growth factors to encourage the stem cells to become liver cells. Then, they heated the combination up to a normal body temperature. The result was a 3-D, biodegradable gel that contained functioning liver cells. The researchers conclude that the same process has promise with some further tweaking for ideal conditions as an injectable tissue engineering technique to treat liver disease without surgery.

###

The authors acknowledge funding from the National Research Foundation of Korea.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 161,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

See more here:
Tonsil stem cells could someday help repair liver damage without surgery

Xia Jie.

Medical entrepreneur Xia Jie, whose company Health 100 owns the largest chain of health clinics in China, plans to open overseas facilities to cater for wealthy clients.

That could result in an investment of about $20 million in a regenerative treatment centre in the resort, making it a Mecca for health tourism and athlete injury rehabilitation.

''We're now negotiating with the local medical teams,'' Mr Xia said yesterday through an interpreter while on a four-day fact-finding mission to Queenstown.

''Health 100 really wants to find beautiful cities around the world to take Chinese patients to and Queenstown is one of them.

''The vision is to bring the very high-end customers to have special treatment which is not carried out elsewhere in the world,'' he said.

Health 100 would invest with existing firms Queenstown Regenerative Medicine (QRM), run by Marcelle Noble, and the Queenstown Skin Institute.

Both have small premises at Remarkables Park in Frankton.

Queenstown Skin Institute director Dr Hans Raetz said Mr Xia had indicated plans for a much larger centre, with sites in Remarkables Park, Jacks Point or the Five Mile development off Frankton Ladies Mile already earmarked.

''The size depends on Mr Xia, but we've been talking between $10 million and $20 million.

Read more from the original source:
Stem cell centre proposed for resort

Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the journal Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.

Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, the research has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.

A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.

According to Dr. Guy Sauvageau, "This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer."

The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.

"These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories," adds Dr. Guy Sauvageau. "Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRIC's medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule."

Context

Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.

Furthermore, it is not necessary for the immunological compatibility between donor and recipient to be perfect, unlike in a bone marrow transplant. However, in most cases the number of stem cells obtained from an umbilical cord is much too low for treating an adult, and its use is confined above all to the treatment of children. With the new molecule UM171 it will be possible to multiply stem cells in culture and to produce enough of them to treat adults, especially those who are not Caucasian, and who because of the lack of donors have limited access to transplants.

Collaborators from the Maisonneuve-Rosemont Hospital, the British Columbia Cancer Agency, the Ontario Cancer Institute and the Fred Hutchison Cancer Research Center also played an important role in evaluating the biological properties of this new molecule, and those from the University of Toronto in developing the bioreactor.

Read more:
New molecule allows for up to 10-fold increase in stem cell transplants

Stem Cell Therapy | why no more news about embryonic stem cells
http://www.arthritistreatmentcenter.com Is embryonic stem cell research passe? Next How come no more news about embryonic stem cells? Embryonic stem cells come from human embryos and these...

By: Nathan Wei

More:
Stem Cell Therapy | why no more news about embryonic stem cells - Video

MISSISSAUGA Dorothy Vernon-Brown is on the search of her life.

When she was diagnosed with acute myaloid leukemia in August, 2013, the Mississauga mother said it was like a huge kick in the gut.

She underwent chemotherapy shortly after the diagnosis, which helped her into remission, but to survive, she has been told her only chance is a bone marrow transplant.

Bone marrow cells rescue patients from the lethal effect of chemotherapy, says Vernon-Browns oncologist, Dr. Mark Minden.

Since starting a relationship with Canadas stem cell and marrow network, One Match, Vernon-Browns search has come up empty.

Vernon-Brown says she is desperate: Recent tests show lower white blood cell counts in her blood an indication the cancer may be coming back.

But shes also worried about how few donors are from the black community. Vernon-Brown has been told her chance of finding a compatible donor are one in 10,000.

Genetics are key in finding potential stem cell and bone marrow donors says, One Match patient and transplant liaison, MaryLynn Pride said.

There is only a 25 per cent chance that even a sibling will be a match, says Pride. We have patients from all ethnic communities that are currently in need of a stem cell transplant.

Black Canadians makes up only 1 percent of all Canadians registered as potential donors, according to Pride.

Link:
Desperate search for bone marrow donor goes private for Mississauga woman

ABC Ralph Bright harvests stem cells using the liposuction.

Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.

An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.

The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.

Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.

He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.

Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).

Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.

Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.

"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.

See more here:
Stem cell harvesting methods used by Sydney doctor Ralph Bright untested by clinical trials

ABC Ralph Bright harvests stem cells using the liposuction.

Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.

An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.

The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.

Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.

He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.

Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).

Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.

Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.

"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.

The rest is here:
Stem cells treatment used by Sydney doctor Ralph Bright 'untested' by clinical trials

Contact Information

Available for logged-in reporters only

Study Links Sex Hormone Levels in the Blood to Risk of Sudden Cardiac Arrest Measuring the levels of sex hormones in patients blood may identify patients likely to suffer a sudden cardiac arrest, a heart rhythm disorder that is fatal in 95 percent of patients. A new study, published online by the peer-reviewed journal Heart Rhythm, shows that lower levels of testosterone, the predominant male sex hormone, were found in men who had a sudden cardiac arrest. Higher levels of estradiol, the major female sex hormone, were strongly associated with greater chances of having a sudden cardiac arrest in both men and women. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Cedars-Sinai Shortens Premature Infants Intensive Care Stays by 21 Percent in Past Three Years The amount of time premature babies spend in Cedars-Sinais Neonatal Intensive Care Unit, part of the Maxine Dunitz Childrens Health Center, has declined dramatically during the past three years, with the average length of stay dropping from 21 days to 17 days. In recent years there have been some notable medical advances, such as personalized nutrition therapy that helps the smallest infants gain weight, nonsurgical procedures to heal heart defects and new medical protocols for mothers likely to deliver a premature infant. All have contributed to more rapidly improving the health of premature infants and shortening the infants hospital stays. But one of the main reasons for the shorter hospitalizations is a renewed emphasis on coordinating each babys various and complex health needs. CONTACT: Soshea Leibler, 213-215-8000; Email soshea.leibler@cshs.org

Combining Antibodies, Iron Nanoparticles and Magnets Steers Stem Cells to Injured Organs Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage. The combined nanoparticle enabled precise localization of the bodys own stem cells to the injured heart muscle. The study, which focused on laboratory rats, was published in the online peer reviewed journal Nature Communications. The study addresses a central challenge in stem cell therapeutics: how to achieve targeted interactions between stem cells and injured cells. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Cedars-Sinai Presents Educational Program on Pituitary Disorders for Patients and Families Disorders of the pituitary gland often cause gradual onset of challenging and difficult-to-manage symptoms, and it is not uncommon for patients to consult doctor after doctor in search of an accurate diagnosis and the hope of treatment. In a one-day conference in Huntington Beach on Sept. 28, pituitary experts from Cedars-Sinai will provide an update for patients and their families on the most recent advances in the diagnosis and treatment of pituitary disorders. Patients will be able to engage in discussions and Q&A sessions with the faculty. CONTACT: Sandy Van, 808-526-1708; Email sandy@prpacific.com

Researchers Developing Noninvasive Method for Diagnosing Common, Painful Back Condition An interdisciplinary research team in the Cedars-Sinai Biomedical Imaging Research Institute, Department of Biomedical Sciences, Regenerative Medicine Institute and Department of Surgery received a grant from the National Institutes of Health (NIH) to develop the first imaging technique used to identify biomarkers that could indicate patients have a painful, degenerative back condition. Biomarkers are certain body substances, such as proteins or body fluids that can indicate specific health conditions. When noninvasive imaging procedures can identify exactly where the biomarkers are, researchers may alleviate the need for painful and invasive diagnostic procedures and, in the future, provide targeted, stem cell-based therapies to patients with the condition. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org

Cedars-Sinais New Comprehensive Transplant Center Opens The new home of the Cedars-Sinai Comprehensive Transplant Center opens Monday and consolidates the clinical and administrative services for liver, kidney, lung and pancreas transplant patients. The four programs were previously housed at several locations on the 24-acre medical center campus, but now transplant patients can have nearly all of their medical needs addressed at one location. The three-story facility covers 36,500 square feet and is located at 8900 Beverly Blvd., two blocks from the main medical center campus. The new center has 22 exam rooms, infusion therapy and phlebotomy services, patient education space and an outpatient procedure room. Two floors of underground parking and valet parking service are available to patients and their families. (High resolution photos available upon request) CONTACT: Laura Coverson, 310-423-5215; Email laura.coverson@cshs.org

View original post here:
Cedars-Sinai Medical Tip Sheet for Sept. 2014

Aired 9/12/14 on KPBS News.

San Diego scientists have taken a neurochemical fingerprint of schizophrenia. And they did it without probing the brains of lab mice.

San Diego scientists have taken a neurochemical fingerprint of schizophrenia. And they did it without probing the brains of lab mice.

UC San Diego's Vivian Hook, first author of a paper published Thursday in Stem Cell Reports, says mice just wouldn't cut it for her research on schizophrenia.

"The basic reason I didn't do it in mice is because mice naturally don't get schizophrenia," Hook said.

Hook and her colleagues tried a fairly new approach. They took skin cells from three schizophrenia patients, converted them into stem cells, and then turned those stem cells into brain cells. They ended up with tiny brain fragments in a dish, which mirrored the cells inside the actual brains of those human patients.

"We found that the schizophrenic neurons showed aberrant increases in certain neurotransmitters. The cells were pumping out more dopamine, norepinephrine and epinephrine than non-schizophrenic brain cells," Hook said. "There's a chemical imbalance that has been predicted in schizophrenia, and these model schizophrenic-derived nerve cells provide data showing that."

Hook says the study also proves that stem-cell derived neurons can secrete neurotransmitters, just like cells in living human brains. That could open up research into new drugs for schizophrenia, and could potentially help answer longstanding questions about conditions like autism, ALS and Alzheimer's.

Follow this link:
Stem Cells Give San Diego Scientists Useful Portrait Of Schizophrenia

GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA
Global Institute of Stem cell Therapy and Research - GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava - Chairman Co-founder of GIOSTAR.

By: Devang Parmar

See the original post:
GIOSTAR- STEM CELL THERAPY & DR ANAND SHRIVASTAVA - Video

4 hours ago

(Phys.org) For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.

The work, as detailed in the journal Stem Cells, shows that only a bit of creative manipulation is needed to turn skin cells into human white blood cells.

"The process is quick and safe in mice," says senior author Juan Carlos Izpisua Belmonte, holder of Salk's Roger Guillemin Chair. "It circumvents long-standing obstacles that have plagued the reprogramming of human cells for therapeutic and regenerative purposes."

Those problems includes the long timeat least two monthsand tedious laboratory work it takes to produce, characterize and differentiate induced pluripotent stem (iPS) cells, a method commonly used to grow new types of cells. Blood cells derived from iPS cells also have other obstacles: an inability to engraft into organs or bone marrow and a likelihood of developing tumors.

The new method takes just two weeks, does not produce tumors, and engrafts well.

"We tell skin cells to forget what they are and become what we tell them to bein this case, white blood cells," says one of the first authors and Salk researcher Ignacio Sancho-Martinez. "Only two biological molecules are needed to induce such cellular memory loss and to direct a new cell fate."

Belmonte's team developed the faster technique (called indirect lineage conversion) and previously demonstrated that these approaches could be used to produce human vascular cells, the ones that line blood vessels. Rather than reversing cells all the way back to a stem cell state before prompting them to turn into something else, such as in the case of iPS cells, the researchers "rewind" skin cells just enough to instruct them to form the more than 200 cell types that constitute the human body.

The technique demonstrated in this study uses a molecule called SOX2 to become somewhat plasticthe stage of losing their "memory" of being a specific cell type. Then, researchers use a genetic factor called miRNA125b that tells the cells that they are actually white blood cells.

The researchers are now conducting toxicology studies and cell transplantation proof-of-concept studies in advance of potential preclinical and clinical studies.

Originally posted here:
Simple method turns human skin cells into immune-fighting white blood cells